PTU - Polskie Towarzystwo Urologiczne
list of articles:

Phosphodiesterase type 5 inhibitors
Article published in Urologia Polska 2004/57/1.


Tomasz Jakubczyk, Krzysztof Pych, Piotr Kryst, Andrzej Borkowski
Katedra i Klinika Urologii Akademii Medycznej w Warszawie
Kierownik kliniki: prof. dr hab. Andrzej Borkowski


phosphodiesterase type 5 inhibitors, erectile dysfunction


It has been over 5 years since March, 27th, 1998, when sildenafil (Viagra, Pfizer Inc.) - the first selective, given orally to men with erectile dysfunction phosphodiesterase type 5 inhibitor gained FDA approval. From that time sildenafil was used by over 20 million of men all over the world. The number of sold tablets exceeded a billion, while at least 2000 papers and abstracts were published on the basis of 120 clinical trials. Nowadays other agents inhibiting phosphodiesterase type 5, eg. tadalafil (Cialis, Lilly ICOS) and vardenafil (Levitra, Bayer) are available. The paper attempts to summarise current knowledge on phosphodiesterase type 5 inhibitors and analyze their features, influencing advantages and disadvantages of each of them.


  1. Eardley I: The role of phosphodiesterase, inhibitors in impotence. Exp Opin Invest Drugs 1997; 6:1803-1810.
  2. Corbin JD. Francis SII. Webb DJ: Phosphodiesterase type 5 asa pharmacologic target in erectile dysfunction. Urology 2002: 60 (suppl. 2B): 4-11.
  3. Lunny C. Baxendale R. Fawcett L, et al: Ablation of phosphodiesterazy type 11 (PDE1 l)in mice by gene knockout induces dianges in spermatozoa function, (abstract) 10th World Congress of the International Society for Sexual and Impotence Research (ISSIR). Montreal, Canada. September 22-26. 2002.
  4. Osterloh I. Eardley I. Carson C. I\\\'adma-Nathan H: Sildenafil: a selective phosphodiesterase (PDE) 5 inhibitor in the treatment of erectile dysfunction (ED). In: Carson C. Kirby R. Goldstein I (Ed) Textbook of Erectile Dysfunction Chapter 26: 285-308.
  5. Qiu Y, Kraft P. Craig EC et al: Cyclic nucleotidephosphodesterases in rabbit detrusor smooth muscle. Urology. 2002: 59: 145-149.
  6. Uckert s. Kuthc A. Jonas U. Stief CG: Characterization and Junctional relevance, of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-2490.
  7. Baxendale RVV, Wayman CR Turner L. et al: Cellular loadisation of phosphodiesterase Type 11 (l\\\'DF.11) in human corpus cavernosum and the contribution of PDE11 inhibition on nerve-stimulated relaxation. Abstract. 2001 AUA Annual Meeting, abstract 922.
  8. O\\\'Donnel JM: William Harvey Research Conference on PDE Inhibitors: drugs with an expanding range of therapeutic uses. Exp Opin Invest Drugs 2000: 9 (3): 621-625.
  9. Porst H, Rosen R. Padma-Nathan H et al: The efficacy and tolerability of vardenafil, anew oral selective phosphodiesterase type 5 inhibitor in patients with erectile dysfunction: the first at-home clinical trial, hit J Impol Res 2001:13 (4): 192-199.
  10. Nehra A, Colreavy F. Khandheria BK, Chandrasekarao K: Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologie and cardiovascular implications. World J Urol 2001:19: 40-45.
  11. Truss MC, Stief CG: Phosphodiesterase inhibitors in the treatment of erectile disjunction. Drugs of Today 1998: 34 (9): 805-812.
  12. Boolell M. Gepi-Attee S, Gingell JC et al: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 76: 257-261.
  13. Montorsi F, Sabnia A. Deho F et al.: Pharmacological management of erectile dysfunction. BJU Int 2003: 91:446-454.
  14. Padma-Nathan H, Rosen RC, Shabsigh R et al: Cialis (IC3S1) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). J Urol 2001; 165 (suppl. 5): 923.
  15. Rolella DP: TadalafilLilly ICOS. Curr Opin Invest Drugs 2003; 4(1): 60-65.
  16. Moncada I. Jara J, Subira D. et al: Efficacy of sildenafil at 12 hours after its intake: re-exploring the therapeutic window. 10™ World congress of the International Society for Sexual and Impotence Research (LSSIR). Montreal, Canada. 22-26.09.2002. Abstract.
  17. Coleman CI. Carabino JM, Vergara CM. Wang F: Vardenafil. Formulary 2003; 38:131-148.
  18. KlmS. Narayan S, SongJC: Tadalafil. An oral selective phosphodiesterase 5 inhibitor for treatment of erectile, dysfunction. Formulary 2002; 37:289-296.\\\"
  19. KbtzT, Sachse R. Heidrich A et al.: Vardenafil increases peiule rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19: 32-39.
  20. Ormrod D. Easthope E. Figgitl DP: Vardenafil. Drugs Aging 2002:19 (3):217-227.
  21. Bauer R). Rohde G, Rajagopalan P: Evaluation of the effects of alcohol, a high-fat breakfast and a moderate-fat evening meal on tlie pharmacokinetics of the PDF. 5 ingibitor vardenafil. Eur Urol 2003: suppl. 2.1:176.
  22. Gbekor E, Sue B, Lindsay F et al: Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 2002:1 (suppl. 1): 63.
  23. Carson CC, Burnett AL., Levine I .A. Nehra A: The efficacy of sildenafil citrate (Viagra) in clinical popidations: an update. Urology 2002: 60 (suppl. 2B): 12-27.
  24. Hafcnchristou DG: Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002:14 (Suppl 1): S43-S52.
  25. Hellstrom WJG, Gittelman M, Karlin G et al: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trud. J Androl 2002; 23 (6): 763-771.
  26. Stark S. Sachse R, Liedl T et al: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40:181-190.
  27. Vezina JG, Nehra A, Brock G et al.: Vardenafil improved patient satisfaction with erection hardness, orgasmic function and sexued experience in men with erectile dysfunctionfollowing neive-sparing radktdprostatectomy. 2003 AUA Annual Meeting, abstract 949.
  28. Brock GB, Mc Mahon CG. Chcm KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated aiudy-ses. J Urol 2002; pl68:1332-1336.
  29. Saenz de Tehada I. Knight JR, Anglin G. Emmick JT: Effects of Tadalafil on Erectile Dysfunction in Men With Diabetes. Diabetes Care 2002; 25:2159-2164,
  30. Brock GB. Iglcsias J, Toulouse K el al.: Efficacy and safety of Cialis (1C351) treatment for F.D (abstract). 2001EAU Congress, abstract 414,
  31. Hatzichristou DG. Pescatori RS: Current treatments and emerging therapeutic approaches in male, erectile dysfunction. BJU International 2001; 88 (Suppl. 3): 11-17.
  32. Hellstrom WJG. Gittelman M. Karlin G, cl al.: Sustained efficacy and to-lerability of vardenafil, a highly potent selective phosphodiesterase type. 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61 (suppl 4A): 8-14.
  33. Porst H. Rosen R. Padma-Nathan H et al: Vardenafil. a new highly selective. PDE5 inhibitor improves erectile function irrespective of the baseline severity and etiology of ED or age of patients. Eur Urol 2001; 39 (suppl. 5): A57.
  34. Hat2ichristou D. Montorsi F, Porst H et al,: A flexible dose regimen of vardenafil for erectile dysfunction: a placebo-controlled trial. Eur Urol 2003: Suppl 2:1:176,
  35. Wallis RM, Corbiri JD, Francis SIT. Ellis P: Tissue distribution of phosphodiesterazc families and the. effects of sildenafil on tissue cyclic nucleotides, platelet function and the contractile responses of tra-beculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C.
  36. Laties A, Zrenner E: Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002 Sep: 21(5): 485-506.
  37. Padma-Nathan I-I, Bardley I. Kloner RA, et al: A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002: 60 (suppl. 2B): 67-90.
  38. Jackson G: Phosphodiesterase 5 inhibition: effects on the coronary vasculature. Int J Clin Pract 2001; 55 (3): 183-188.
  39. Vardi Y, Klein L, Nassar S, et al: Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 2002: 59: 747-752.
  40. Jackson G. Benjamin N, Jackson N, Allen MJ: Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 4. 83 (5A): 13C-20C.
  41. Zusman RM. Morales A, Glasser DB. Oslcrloh ICH: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999:4, 83 (5A): 35C-44C.
  42. Morales A. Gingell C. Collins M et al: Cluneal Sitfely of oral sildenafil citrate (Viagra) in the treatmetn of erectile dysfunction. Int J Impot Res 1998;10:69-74.
  43. Geelen P, Benoit I). Rail J. et al: Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid componenet of the delayed rectifier potassium current. Circulation, 2000; 102: 275-277.
  44. Shakir SAW et al: Cardiovasadar events in users of sildenafil: results from first phase of prescription event mimloring in Bngleand. BMJ 2001; 322:651-652.
  45. Patrizi R, Leonardo P. Pelliccia F. el al: Effect of sildenafil citrate upon myocardial ischemia in [xitients with chronic stable angina in therapy with beta-blockers. Ital Heart J 200: 2 (11): 841-844,
  46. Bocchi EA. Guimaraes G, Mocelin A et al: Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. Circulation 2002:106:1097-1.103.
  47. Thadani U. Smith W, Nash S. et al: The effect of vardenafil. a potent and highly selective phosphodiesterases inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease, J Am Coll Cardiol 2002 4; 40 (11): 2006-2012.
  48. Fox KM. Thadani U, M PT, Nash SD: Time, to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate (abstract). Circulation 2001:107:n 60i.
  49. Ockaili R, Salloum F. Hawkins J, Kukreja C: Sfldenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K±jy channels in mbbits. Am J Physiol Heart Ore Physiol 2002: 283: H1263-H1269,
  50. Conti CR. Pepine CJ. Sweeney M: Efficacy and safety of sildenafil citrate in the treatment of erectde dysfunction in patients with ischemic heart disease. Am J Cardiol 1999 4: 83 (5A): 29C-34C.
  51. Kloner RA: Sex ami the. patient with cardiovascular risk factors: focus on sildenafil. Am J Med 2000; 18; 109. 9A: 13S-21S.
  52. Abdel-Hamid IA. Naggar EA. El Gilany AH: Assessment of as needed use of pharmacotherapy and the pause-squeese technique in premature ejaculation. Int J Impot Res 2001; 13: 41-45.
  53. Lozano AF, Castane ER. Barcelona S: Premature ejaculation: sildenafil plus setraline versus sertraline alone and sildenafil alone. 2003 Annual AUA Meeting, abstract 956.
  54. D\\\'Amati G. di Gioia CR, Bologna M. et al: Type 5 phosphodiesterase expression in the human vagina. Urology 2002; 60:191-1.95.
  55. Caruso S. Intelisano G. Lupo L et al: Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obstet Gynaecol 2001; 120: 305-306,
  56. Sher G. Fish JD; Vaginal sildenafil (Viagra): a preliminary report o a novel method to improve uterine artery blood flow and endometrial development inpatients undergoing NF. Hum Reprod 2000; 15 (4): 806-809.
  57. , Giuliano F, Montorsi F, Mironc V. et al: Swichtchingfrom imracaverno-us prostagladiun El injections to oral sildenafil citrate in patients with erectile dysfunction. Results of a multicenter European study. J Urol 2000:164:708-711.
  58. asp#survey
  59. http: //www. fda. gov
  60. Turgeon J. Geelen P, Drolet B et al: Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid componenet of the delayed rectifier po-tassium current (Response to Comment). Circulation 2001; 103 (23): el!9-el20.
  61. Phillips BG, Kato M. Pesek CA et al; Sympathetic activation by sildenafil. Circulation 2000; 102: 3068-3073.
  62. DeRose AF, Giglio M, Traverso P, et al.: Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int. J Impot Res 2002; 14: 50-53.
  63. Hopps CV Mulhall JP: Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). 2003 Annual ALA Meeting, abstract 1401.


Tomasz Jakubczyk
Katedra i Klinika Urologu AM
ul. Linleya 4
02-005 Warszawa